Todos os estudos
RecrutamentoFASE3INTERVENCIONISTA

A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of GM1 Gangliosidosis or GM2 Gangliosidosis

This study is testing a new medicine, AZ-3102, for children and young people who have GM1 or GM2 gangliosidosis, which are rare genetic conditions. The main goal is to find out if this medicine can safely improve problems with balance and coordination that are common with these conditions. For 18 months, some participants will receive the active medicine, while others will receive a placebo (a dummy pill with no active ingredients). This is to help doctors understand the true effect of AZ-3102. Researchers will also look at other symptoms, how the body handles the medicine, and any side effects. This is a large, important study taking place at multiple hospitals.

Em resumo

Status
Recrutamento
Fase
FASE3
Patrocinador
Azafaros B.V.
Meta de inscrição
75
Iniciar
30 Jun 2025
Conclusão estimada
06 Mar 2028

Sobre o que é este estudo?

This study is designed to learn more about a new medicine called AZ-3102. It's for children and young people who have a rare genetic condition called GM1 or GM2 gangliosidosis. These conditions can cause various problems, including difficulties with movement and balance, which doctors call 'ataxia'. The main purpose of this study is to see if AZ-3102 can help improve these balance and movement issues safely.

To make sure we get clear results, the study will last 18 months and involve two groups of participants. One group will receive the new medicine, AZ-3102, and the other group will receive a 'placebo'. A placebo looks exactly like the medicine but doesn't contain any active ingredients. Neither the participants, their families, nor the study doctors will know who is getting the medicine and who is getting the placebo – this is called a 'double-blind' study. This method helps ensure that any improvements or changes observed are truly due to the medicine and not just other factors.

Beyond just looking at balance problems, the researchers will also check if the medicine helps with other symptoms of GM1 or GM2 gangliosidosis. They will also carefully monitor how the body uses and processes the medicine (this is called pharmacokinetics) and how it affects the body (pharmacodynamics). Most importantly, they will be closely watching for any side effects or safety concerns to make sure the medicine is well-tolerated. This is a Phase 3 study, which means it's a critical step before a new medicine can potentially become widely available.

Pontos principais

  • This study is testing a new medicine (AZ-3102) for GM1 and GM2 gangliosidosis.
  • The main goal is to see if it helps with balance and movement problems.
  • It's a long study (18 months of treatment) with regular hospital visits.
  • Participants will receive either the medicine or a dummy pill, and no one will know which.
  • Safety and potential side effects will be closely monitored throughout the study.
  • Participation helps advance understanding of these rare conditions.

Quem pode ser elegível?

To be considered for this study, your child must have been diagnosed with either GM1 gangliosidosis or a specific type of GM2 gangliosidosis (Tay-Sachs, Sandhoff, or GM2AB variant). They need to be at least 4 years old and have started showing neurological symptoms of their condition between the ages of 1 and 10 years.

Crucially, your child also needs to have noticeable problems with balance and coordination. Doctors will use a special scoring system, and your child's score needs to be within a certain range to qualify. If your child is a girl who could become pregnant, or a boy with a partner who could become pregnant, you'll need to agree to use effective contraception during the study.

There are also some reasons why your child might not be able to join the study. For example, if they have another serious medical condition that isn't GM1 or GM2, or certain kidney or liver problems. Children weighing less than 10kg, or those who have recently changed their anti-epilepsy medicine, or have taken other new experimental drugs recently, would also not be able to participate. This is all to ensure the study is as safe and accurate as possible for everyone involved.

Este estudo pode ser adequado para você?

Responda a estas perguntas rápidas para ver se você pode ser elegível. Este é apenas um guia — a decisão final é da equipe de pesquisa.

  1. Has my child been diagnosed with GM1 or a specific type of GM2 gangliosidosis (Tay-Sachs, Sandhoff, or GM2AB variant)?
  2. Is my child 4 years old or older?
  3. Did my child's neurological symptoms start between the ages of 1 and 10 years?
  4. Does my child have noticeable balance and coordination problems?
  5. Does my child weigh at least 10 kg?
Responda a todas as perguntas para ver o seu resultado.

O que envolve a participação?

If your child takes part, they will receive either the study medicine (AZ-3102) or a dummy pill (placebo) by mouth every day for 18 months. You and the study team won't know which one they are getting. Throughout this period, your child will have regular visits to the hospital or clinic. These visits will involve various tests and assessments to check their balance, movement, and other symptoms. Blood and urine samples will also be taken to see how the medicine is working and to monitor their health. The study team will closely monitor for any side effects. After the 18 months of treatment, there will likely be follow-up appointments to check on your child's health after they stop taking the study medicine. The total duration of active participation, including screening and follow-up, will be longer than 18 months.

Riscos e benefícios potenciais

Taking part in a study like this means you're helping doctors learn more about GM1 and GM2 gangliosidosis, which could benefit many children in the future. If your child receives the active medicine, there's a chance it might help improve their balance and movement problems. However, it's also possible they could receive the dummy pill, in which case there would be no direct medical benefit from the study treatment itself. Like all medicines, AZ-3102 could have side effects, some of which might not be known yet. The study team will explain all known and potential risks in detail. You and your child can choose to leave the study at any time, for any reason, without it affecting your child's usual medical care.

Locations (36)

  • UCSF Children's Hospital and Research Center at Oakland
    Código postal verificado
    Oakland, Estados Unidos· Recrutamento
  • University of Minnesota Medical School
    Código postal verificado
    Minneapolis, Estados Unidos· Ainda não recrutando
  • Mayo Clinic Children's Center - PIN
    Código postal verificado
    Rochester, Estados Unidos· Recrutamento
  • Children's Medical Center Dallas
    Código postal verificado
    Dallas, Estados Unidos· Recrutamento
  • Lysosomal Rare Disorders Research and Treatment Center
    Código postal verificado
    Fairfax, United States· Recrutamento
  • Hospital Universitario Austral
    Apenas cidade
    Ciudad Autónoma Buenos Aires, Argentina· Recrutamento
  • Hospital de Niños de La Santisima Trinidad
    Código postal verificado
    Córdoba, Argentina· Recrutamento
  • Women's and Children's Hospital
    Código postal verificado
    North Adelaide, Australia· Recrutamento
  • Hospital Infantil Real de Melbourne - PIN
    Código postal verificado
    Parkville, Austrália· Ainda não recrutando
  • Instituto Fernandes Figueira
    Código postal verificado
    Rio de Janeiro, Brazil· Recrutamento
  • Hospital de Clinicas de Porto Alegre (HCPA) - PPDS
    Código postal verificado
    Porto Alegre, Brazil· Recrutamento
  • Hospital Pequeno Principe
    Código postal verificado
    Curitiba, Brazil· Ainda não recrutando

Perguntas frequentes

What is GM1 or GM2 gangliosidosis?

These are rare genetic conditions that can affect the brain and body, often causing problems with movement, balance, and other symptoms.

What does 'double-blind, placebo-controlled' mean?

It means neither the patient, their family, nor the doctors will know who is getting the real medicine and who is getting a dummy pill. This helps us get clearer results.

Is AZ-3102 a cure for these conditions?

This study is testing if AZ-3102 can safely improve symptoms, especially balance problems. It's not yet known if it can cure the conditions.

How long will my child need to take part?

The main treatment part of the study lasts for 18 months, but there will be screening and follow-up visits before and after, making the total involvement longer.

What if my child experiences side effects?

The study team will carefully monitor your child's health and any side effects. You should always tell them about any new symptoms or concerns right away.

Como saber mais

Patient Advocacy Representative

Sempre consulte seu médico ou especialista antes de decidir participar de um estudo.

Interessado em participar?

Registre seu interesse

Compartilhe seus detalhes e a equipe de pesquisa para "A Study to Evaluate the Safety and Efficacy of Oral Nizubagl…" entrará em contato com você se você for elegível. Sempre fale com seu médico antes de concordar em participar.

Discussão

Discussão da comunidade

Desenvolvido pelo nosso fórum em community.patient.info. Por favor, seja respeitoso — isto não é um conselho médico.